Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06488313 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD
A Phase 2 study of Ornithine Transcarbamylase Deficiency and OTC Deficiency, sponsored by Arcturus Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT06488313: Recruiting Phase 2 study of Ornithine Transcarbamylase Deficiency and OTC Deficiency, sponsored by Arcturus Therapeutics.
NCT06488313 is a Phase 2 study of Ornithine Transcarbamylase Deficiency and OTC Deficiency that is actively recruiting participants, run by Arcturus Therapeutics. The registered enrollment target is 9 participants, below the 65-participant average among 4 other Ornithine Transcarbamylase Deficiency trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06488313, a Phase 2 study of Ornithine Transcarbamylase Deficiency and OTC Deficiency, is actively recruiting participants, sponsored by Arcturus Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
Evaluate the safety and pharmacodynamics of multiple doses of ARCT-810 in adolescent and adult participants with OTC deficiency.
Primary Outcome
Safety and tolerability of ARCT-810 assessed by incidence, severity, and dose-relationship of AEs
Conditions Studied
Interventions
- BIOLOGICAL ARCT-810
Study Locations (1)
Maryland
- Uncommon Cures - Chevy Chase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2024-11-04 |
| Est. Completion | 2026-09-01 |
| Phase | Phase 2 |
What NCT06488313 shows while recruiting
NCT06488313 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 65-participant average among 4 other Ornithine Transcarbamylase Deficiency trials with a reported enrollment target (86% lower).
The record links to 3 conditions, with Ornithine Transcarbamylase Deficiency appearing as the primary indexed condition, and to 1 intervention - of which ARCT-810 is the first listed.
NCT06488313 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT06488313 about?
NCT06488313 is a clinical study titled "A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD". Evaluate the safety and pharmacodynamics of multiple doses of ARCT-810 in adolescent and adult participants with OTC deficiency.
What is the current status of trial NCT06488313?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2024-11-04. Estimated completion is 2026-09-01.
What conditions does trial NCT06488313 study?
This clinical trial studies the following conditions: Ornithine Transcarbamylase Deficiency, OTC Deficiency, OTCD.
What interventions are being tested in trial NCT06488313?
The interventions under investigation include: ARCT-810 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06488313?
This trial is sponsored by Arcturus Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06488313 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ornithine Transcarbamylase Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Liver Disease in Urea Cycle Disorders
RECRUITING
-
An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency
RECRUITING · Phase 1
-
Hepatic Histopathology in Urea Cycle Disorders
RECRUITING
-
A Study to Assess Plasma Ammonia Time-Normalized Area Under the Curve and Rate of Ureagenesis in Healthy Adult Subjects
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI